Kristina Lübbe

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert, Fenja Seither, Andreas Schneeweiß et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Cancer Biology, Oncology +16

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 122 citations

Medicine, Gynecology, Oncology +13

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial

Volkmar Müller, Stephan Gade, Bettina Steinbach et al. · Breast Cancer Research and Treatment · 2014 · 121 citations

Medicine, Cancer Biology, Oncology +16

Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial

Andreas Schneeweiß, Volker Möbus, Hans Tesch et al. · European Journal of Cancer · 2018 · 107 citations

Medicine, Oncology, Pharmacology +14

Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer

Esther Pohl‐Rescigno, Jan Hauke, Sibylle Loibl et al. · JAMA Oncology · 2020 · 64 citations · Full text

Medicine, Oncology, Pharmacology +17